Secukinumab-induced erythema multiforme-like drug eruption in generalized pustular psoriasis: a case report and literature review

Secukinumab is an IL-17A inhibitor that selectively binds to IL-17A and inhibits its interaction with IL-17 receptors, thereby reducing the production of pro-inflammatory cytokines, chemokines, and tissue-damaging mediators. Secukinumab has been proven to rapidly improve erythema and pustules in adult and paediatric generalized pustular psoriasis (GPP) patients. Here, we report a case study of erythema multiforme-like drug eruption induced by secukinumab and provide an overview of all cases reported so far. A systematic literature search of publications was conducted from inception to September 2024 via PubMed and Web of Science Core Collection, in order to identify all cases of drug hypersensitivity reactions associated with secukinumab. We conducted a search for retrospective and prospective studies, case series, case reports, and data from Phase II and III clinical trials related to immune-related (or potentially immune-related) adverse events associated with the use of secukinumab. In total, four cases of drug hypersensitivity reactions associated with secukinumab were identified. Drug hypersensitivity reactions associated with secukinumab are relatively rare. The recognition of potential rare adverse events by clinicians is important and may expand our understanding of immune-mediated diseases.